Evidence-based cardiovascular therapies for patients with diabetes or metabolic syndrome

Evidence-based cardiovascular therapies for patients with diabetes or metabolic syndrome is organized by American Heart Association (AHA).

Release Date: 03-14-2018
Expiration Date: 03-14-2021

Accreditation:
AMA Credit Designation Statement - Physicians
The American Heart Association designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits™.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.75 hours of Category 1 credit for completing this program.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 0.75 contact hours.

ACPE Credit Designation Statement – Pharmacists
ACPE Credit: 0.75 Contact Hours.

Continuing Education Accreditation – Emergency Medical Services
This continuing education activity is approved by the American Heart Association, an organization accredited by the Commission on Accreditation of Pre-Hospital Continuing Education (CAPCE), for 0.75 Advanced CEHs.

Objectives:
At the completion of this online course, the learner will be able to:
• Translate emerging clinical science to clinical practice in patients with cardiovascular disease and stroke.
• Evaluate and implement new diagnostic and therapeutic strategies for treating cardiovascular disorders and stroke.
• Demonstrate an understanding of newly developed concepts in the care of patients with common cardiovascular problems including atrial fibrillation, hypertension, heart failure, and dyslipidemia.
• Describe treatment strategies for cardiovascular problems that can be deployed in the outpatient setting and keep patients out of the hospital.
• Describe treatment strategies for cardiovascular problems in the setting of common comorbidities.
• Describe the relative merits of new therapies for cardiovascular problems with respect to efficacy and cost.